Is the price fair?
What WRBY's price assumes
Warby Parker Inc. has no trailing P/E on file, so the price is measured against sales instead: 2.97× revenue.
2.97
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 1.1%
Free cash flow yield · Medical Instruments & Supplies median 3.7%
- Growth the price implies
- +25%
Growth the price implies · The price pays for +25% free cash flow growth a year for a decade; revenue has grown +13% a year over the last three.
- Price / book
- 7.04
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 7.04
- EV / EBIToperating margin −0.69%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $39M
- Market capitalisation
- $3.37B
- 3-year revenue growth
- +13%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Instruments & Supplies
Ranks #18 of 19 by Smart Score